Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2019 07:00 ET | Source: Zafgen, Inc.

Zafgen to Explore Strategic Alternatives

BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
August 08, 2019 16:15 ET | Source: Zafgen, Inc.

Zafgen Reports Second Quarter 2019 Operating and Financial Results

Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study...
August 06, 2019 16:15 ET | Source: Zafgen, Inc.

Zafgen to Present at the Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
July 24, 2019 16:15 ET | Source: Zafgen, Inc.

Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061

Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the...
June 13, 2019 16:15 ET | Source: Zafgen, Inc.

Zafgen to Present at the JMP Securities Life Sciences Conference

BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
June 10, 2019 07:00 ET | Source: Zafgen, Inc.

Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions

Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data...
May 30, 2019 07:00 ET | Source: Zafgen, Inc.

Zafgen Announces Regulatory Update on ZGN-1061

Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression...
May 09, 2019 16:15 ET | Source: Zafgen, Inc.

Zafgen Reports First Quarter 2019 Operating and Financial Results

Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company is currently in the formal regulatory process related to the clinical hold for...
May 02, 2019 16:30 ET | Source: Zafgen, Inc.

Zafgen to Announce First Quarter 2019 Financial Results

BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
April 04, 2019 16:30 ET | Source: Zafgen, Inc.

Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to...